3 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow felzartamab: new trials by email Literature Review of felzartamab trials Research Report on felzartamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old Felzartamab - Lupus Nephritis | Phase 1 | Completed | HI-Bio, A Biogen Company | 14 | 2023-11-01 | 2026-07-17 |
| Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) MOR202 - Glomerulonephritis, Membranous, antiPLA2R Positive | Phase 1 / Phase 2 | Completed | HI-Bio, A Biogen Company | 31 | 2019-10-15 | 2025-02-24 |
| A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma MOR03087 phase 1 dose escalation, MOR03087, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | MorphoSys AG | 91 | 2011-07-01 | 2021-11-16 |
Glomerulonephritis, Membranous (1) · Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1) · Multiple Myeloma (1)
HI-Bio, A Biogen Company (2) · MorphoSys AG (1)
Australia (2) · United States (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1)